

Pneumatosis Cystoides Intestinalis After Gefitinib Therapy for Pulmonary Adenocarcinoma

Masahiro Iwasaku, MD,* Hiroshige Yoshioka, MD,* Yohei Korogi, MD,* Kei Kunimasa, MD,* Akihiro Nishiyama, MD,* Hiroki Nagai, MD,† and Tadashi Ishida, MD, PhD*

An 82-year-old female with right chest pain was referred to our hospital. She was diagnosed with adenocarcinoma of the lung with pleural dissemination and bone metastases. She was treated with oral gefitinib (250 mg once daily). At first, there was no apparent adverse event except for mild diarrhea. Two months after the first administration of gefitinib, she presented with mild abdominal pain, with the computed tomography revealing extensive intramural air within the intestinal wall, extending from the duodenum to the ascending colon, without portal venous air (Figure 1). A physical examination indicated no sign of toxicity, with the condition being presumed as pneumatosis cystoides intestinalis (PCI). Gefitinib was stopped and careful monitoring with dietary restriction was done. The symptoms gradually improved by conservative therapy and a follow-up computed tomography showed no sign of intramural air. Although gefitinib was readministered, the same episode repeated three times during gefitinib therapy.

PCI is a rare condition that is characterized by intramural gas in the gastrointestinal tract, and its patho-




FIGURE 1. Computed tomography at first onset of pneumatosis cystoides intestinalis demonstrating pneumatosis extending from the duodenum to the ascending colon.

genesis is unknown.^{1,2} Although various chemotherapeutic agents have been reported to be associated with PCI, there have been no reports that addressed the association between PCI and gefitinib.

REFERENCES

1. Heng Y, Schuffler MD, Haggitt RC, et al. Pneumatosis intestinalis: a review. *Am J Gastroenterol* 1995;90:1747-1758.
2. Pear BL. Pneumatosis intestinalis: a review. *Radiology* 1998;207:13-19.

*Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki and †Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Disclosure: The authors no declare no conflicts of interest.

Address for correspondence: Hiroshige Yoshioka, MD, Department of Respiratory Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki 710-8602, Japan. E-mail: hirotin@kch.net.or.jp

Copyright © 2011 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/12/0701-0257